Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Chemotherapy-induced myelosuppression.

M B Maxwell1, K E Maher

  • 1Department of Nursing, VA Medical Center, Portland, OR 97207.

Seminars in Oncology Nursing
|May 1, 1992
PubMed
Summary

Chemotherapy-induced myelosuppression, a serious cancer treatment side effect, has seen limited success with past interventions. New hematopoietic growth factors offer potential benefits, but their precise clinical application requires further definition.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Radiation therapy for prostate cancer.

Seminars in oncology nursing·2001
Same author

Organ preservation.

Seminars in oncology nursing·1999
Same author

Non-physician practitioners in radiation oncology: advanced practice nurses and physician assistants.

International journal of radiation oncology, biology, physics·1999
Same author

Stem cell transplantation in advanced breast cancer.

The American journal of nursing·1998
Same author

A comparison of intravenous nicardipine and sodium nitroprusside in the immediate treatment of severe hypertension.

American journal of hypertension·1994
Same author

Cancer of the prostate.

Seminars in oncology nursing·1993

Area of Science:

  • Oncology
  • Hematology

Background:

  • Chemotherapy-induced myelosuppression is a frequent, severe complication of cancer therapy.
  • Existing methods to mitigate myelosuppression have shown minimal efficacy.

Purpose of the Study:

  • To evaluate the potential of novel hematopoietic growth factors in managing chemotherapy-induced myelosuppression.
  • To highlight the need for defined clinical guidelines for growth factor application.

Main Methods:

  • Review of current literature on chemotherapy-induced myelosuppression.
  • Analysis of emerging data on hematopoietic growth factors.

Main Results:

  • Hematopoietic growth factors demonstrate promise for patients undergoing myelotoxic chemotherapy.
  • Current data suggests potential benefits, but further research is needed.

Conclusions:

  • Novel hematopoietic growth factors represent a promising therapeutic avenue for chemotherapy-induced myelosuppression.
  • A cautious and evidence-based approach is essential for integrating growth factors into clinical practice.

Related Experiment Videos